Monday, May 15, 2017

Gilead Sciences (NASDAQ:GILD)

  • Gilead (GILD) revenues have been declining every quarter for some time now.
  • As long term and recent shareholders are well aware, this has had a very negative impact on the share price.
  • Despite declining revenues from HCV sales, we believe that the company will eventually succeed in diversifying itself and finding new revenue streams.
See the full Seeking Alpha article HERE

No comments:

Post a Comment